In a rare legal defeat, Bristol Myers Squibb and Sanofi fined $834M for 'deceptive marketing' on best-selling blood thinner Plavix
By the time the FDA slapped a black box warning on Plavix in 2010, the blockbuster blood thinner had been on the market for 13 years and reaped billions of dollars — enough to give it a solid spot among the best-selling drugs of all time even to this day, despite reaching peak sales in 2011.
On Monday, a judge in Hawaii sided with the state in ordering its makers, Bristol Myers Squibb and Sanofi, to hand back $834 million of that.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.